Mortality prediction in patients with severe septic shock: a pilot study using a target metabolomics approach by Ferrario, M. et al.
1Scientific RepoRts | 6:20391 | DOI: 10.1038/srep20391
www.nature.com/scientificreports
Mortality prediction in patients 
with severe septic shock: a pilot 
study using a target metabolomics 
approach
Manuela Ferrario1,*, Alice Cambiaghi1,*, Laura Brunelli2,*, Silvia Giordano2, Pietro Caironi3,4, 
Luca Guatteri5, Ferdinando Raimondi6, Luciano Gattinoni3,4, Roberto Latini2, Serge Masson2, 
Giuseppe Ristagno2 & Roberta Pastorelli2
Septic shock remains a major problem in Intensive Care Unit, with high lethality and high-risk 
second lines treatments. In this preliminary retrospective investigation we examined plasma 
metabolome and clinical features in a subset of 20 patients with severe septic shock (SOFA score 
>8), enrolled in the multicenter Albumin Italian Outcome Sepsis study (ALBIOS, NCT00707122). 
Our purpose was to evaluate the changes of circulating metabolites in relation to mortality as a 
pilot study to be extended in a larger cohort. Patients were analyzed according to their 28-days 
and 90-days mortality. Metabolites were measured using a targeted mass spectrometry-based 
quantitative metabolomic approach that included acylcarnitines, aminoacids, biogenic amines, 
glycerophospholipids, sphingolipids, and sugars. Data-mining techniques were applied to evaluate 
the association of metabolites with mortality. Low unsaturated long-chain phosphatidylcholines 
and lysophosphatidylcholines species were associated with long-term survival (90-days) together 
with circulating kynurenine. Moreover, a decrease of these glycerophospholipids was associated to 
the event at 28-days and 90-days in combination with clinical variables such as cardiovascular SOFA 
score (28-day mortality model) or renal replacement therapy (90-day mortality model). Early changes 
in the plasma levels of both lipid species and kynurenine associated with mortality have potential 
implications for early intervention and discovering new target therapy.
Septic shock is the most severe complication of sepsis and is one of the main causes of death in intensive care units 
(ICUs)1. Although treatment has improved over the last decades, outcome is still poor and difficult to predict2. 
Indeed, the majority of patients with shock develops a multiple organ dysfunction syndrome (MODS), a con-
dition in which organs not directly affected by the original infection become dysfunctional, and that ultimately 
represents the main cause of death3. The interrelationship between inadequate oxygen delivery to peripheral 
tissues, ischemia and reperfusion injury in the organs, hemodynamic instability, inflammation and development 
of MODS has been extensively investigated, but the molecular mechanisms which ultimately trigger tissue func-
tional injury remain largely undetermined2.
In the recent, large, multicenter, randomized clinical trial ALBIOS (Albumin Italian Outcome Sepsis study, 
NCT00707122) that enrolled 1818 patients with severe sepsis or septic shock, 90-day mortality of the latter 
patients was 46.7%4. Given this high rate, similar to that observed in other comparable clinical studies5,6, a mul-
timarker strategy may be helpful to better understand the complex pathogenesis of the disease and its evolution, 
especially for early risk stratification and implementation of personalized therapies. The use of emerging omics 
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tools able of examining physiological responses at system level is particularly promising for complex and hetero-
geneous conditions such as septic shock.
Indeed, several recent studies have focused on investigating plasma metabolomic profiles as predictive sig-
natures of ICU mortality in adult patients7–10. Different composite metabolite patterns have been identified with 
nuclear magnetic resonance (NMR) or mass spectrometry (MS). Although these methods have different intrinsic 
metabolomic coverage potential, they all clearly highlight the widespread metabolic abnormalities in patients 
with septic shock, and the interplay of several different biochemical pathways.
In the present study, we used a targeted mass spectrometry-based quantitative metabolomics approach focus-
ing our attention on several series of metabolites, such as glycerophospholipids, aminoacids, biogenic amines and 
acylcarnitines, some of which have already been identified as part of key biochemical pathways in septic shock. 
Metabolic signatures showing alteration in circulating kynurenine, fatty acids, lysophosphatidylcholines species 
and /or carnitine esters have already been reported in different settings of septic shock patients7–16, pointing 
toward an overall derangement of energy circuits, lipid homeostasis and indicating that, probably, the magnitude 
of these changes might provide an indicator of disease severity.
We applied our metabolomic strategy on a selected subset of patients with severe septic shock (serum lactate 
concentration > 4 mmol/L) with multiple organ failures (SOFA score > 8) enrolled in the ALBIOS study. The 
severe condition under study is, fortunately, not frequent in septic shock patients, but it represents a pathological 
state associated with a mortality of 20% in the next 24 hours17.
Our explorative study was designed to provide absolute quantitative information on changes in plasma metab-
olite levels measured one day (initial acute phase) and one week after development of severe septic shock in ICU, 
and to relate these changes with mortality. The two time points were chosen to verify the hypothesis that the 
metabolic changes over the time period reflect not only initial clinical characteristics but also the progression 
of the disease and long-term survival. Association between metabolic patterns and mortality was assessed with 
univariate and multivariate analyses adjusted for clinical relevant variables.
The primary goal of this pilot investigation was to verify the feasibility of our metabolomic approach (e.g. 
metabolic profiles characterizing non-survivors) that is intended to be used in our ongoing larger scale study 
ShockOmics (NCT02141607), aimed at elucidating early multilevel markers signatures which could reveal the 
metabolic pathways involved, a necessary step for a actual target therapy.
Results
Clinical characteristics of the study population. All the patients with severe septic shock enrolled in 
the multicenter ALBIOS clinical trial4, and fulfilling the inclusion/exclusion criteria presented in details in the 
Methods section were analyzed. The data are summarized in the flow chart (Fig. 1). The baseline characteristics of 
these 20 patients are shown in Table 1. On day 28, mortality rate was 45% (9 patients), whereas on day 90 mortal-
ity rate was 55% (11 patients). Clinical variables on days 1 and 7 are shown in Table 2. In 11 patients (55%), source 
of infections was identified at site culture, including gram-negative (5 patients), gram-positive (2 patients) and 
both gram-negative and gram-positive bacterial infection (3 patients), as well as fungal infection (1 patient). In 
Figure 1. Flow chart, which displays the progress of patient selection from the ALBIOS biobank according 
to our inclusion/exclusion criteria. 
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9 of these patients (82%), antibiotic therapy empirically administered during the first 24 hours was appropriate. 
Patients were randomized to receive either 20% albumin and crystalloid solutions (13 patients) or crystalloid 
solutions alone (7 patients) for volume replacement. All the patient were treated according to the standard guide-
lines internationally accepted for the treatment of patients with severe sepsis or septic shock18.
Time-course of plasma metabolites and association with mortality. We applied a mass 
spectrometry-based quantitative metabolomic profiling in order to unambiguously identify and quantify lipids, 
aminoacids, biogenic amines and acylcarnitines in the plasma of the study subjects. To ensure data quality and 
robust statistical analysis the following filtering criteria were applied: (i) metabolites measured with more than 
20% missing data (no detectable peak) were excluded for any further data elaboration; (ii) metabolites for which 
the plasma concentration was below the limit of detection (< LOD) in at least ≥ 50% of analyzed samples were 
excluded.
In total, 137 metabolites were selected after quality control: 1 hexose, 21 amino acids, 14 biogenic amines, 3 
acylcarnitines, 14 sphingomyelins (SM), 84 glycerophospholipids. Concentrations of all analyzed metabolites for 
each patient are expressed as μ M and shown in Table S1 for day 1 (D1) and Table S2 for day 7 (D7).
We first assessed by univariate analysis whether metabolite levels significantly changed from D1 to D7, 
after stratification by survival status. Figure 2 gives a pictorial overview of the changes of metabolite concen-
trations (row, mean Log2 μ M) between D1 and D7 in survivors (S, Fig. 2a) and non-survivors (NS, Fig. 2b) 
(Wilcoxon test p < 0.05, FDR < 0.15, Table S3). Ten different species of lysophosphatidylcholines (LPC), 17 of 
diacyl-phosphatidylcholines (PC aa), 30 of acyl-alkyl phosphatidylcholines (PC ae), 2 of acylcarnitines (carni-
tine, C0; butyrylcarnitine, C4), 4 of long-chain sphingomyelins (SM) increased from D1 to D7 in 28- and 90-day 
survivors, while kynurenine (KYN) and two polyunsaturated diacyl-PC (PC aa C38:6, PC aa C40:6) decreased 
(Fig. 2a). NS at 28 or 90 days showed an overall increase from D1 to D7 for LPC, PC, and SM species. In NS, 
aminoacids doubled their plasma concentration together with putrescine and spermidine, the last one significant 
only in NS at day 90 (Fig. 2b).
Clinical variable ALL S NS pValue
# patients 20 9 (45%) 11 (55%)
Age (yrs) 66.1 ± 13.9 61.3 ± 15.2 69.9 ± 12 n.s.
BMI 27 ± 4 27.6 ± 4 26.5 ± 4 n.s.
Sex (males) 65% 44.4% 81.8% n.s.
Coexisting diseases:
Liver disease (#pts) 0 0 0 n.s.
COPD (#pts) 2 1 1 n.s.
Chronic renal failure (#pts) 0 0 0 n.s.
Immunodeficiency (#pts) 0 0 0 n.s.
Congestive or ischemic heart 
disease (#pts) 2 1 1 n.s.
SAPS II score 57.5 ± 14.9 54.8 ± 17.9 61.1 ± 9.4 n.s.
SOFA score 11.4 ± 1.9 10.5 ± 1.5 12.1 ± 2 n.s.
MAP (mmHg) 68.6 ± 14.4 70.7 ± 16.7 66.8 ± 12.7 n.s.
CVP (mmHg) 12.6 ± 6 13.3 ± 6 12.1 ± 6 n.s.
PEEP (cmH2O) 7.4 ± 3.7 6.2 ± 4.3 8.3 ± 3 n.s.
FiO2 (%) 65 ± 19.3 63.3 ± 17.4 66.4 ± 21.6 n.s.
ScvO2 (%) 73.2 ± 9.6 70.3 ± 10.4 75.6 ± 8.1 n.s.
PvCO2 (mmHg) 43.3 ± 6.9 45.6 ± 6.3 41.3 ± 6.8 n.s.
PaCO2 (mmHg) 38.1 ± 6.9 38 ± 5 38.2 ± 8.9 n.s.
Serum lactate (mmol/L) 7.3 ± 2.4 7.9 ± 2.7 6.8 ± 2.2 n.s.
Platelet count (x103 cells/mm3) 79.4 ± 51.6 79.8 ± 47.4 79.2 ± 57.4 n.s.
Serum Creatinine (mg/dL) 2.3 ± 0.9 2.3 ± 0.9 2.2 ± 1 n.s.
Serum Biliuribin (mg/dL) 2.6 ± 2.9 1.1 ± 0.5 3.8 ± 3.6 0.018
Arterial pH 7.33 ± 0.91 7.32 ± 0.1 7.34 ± 0.1 n.s.
PaO2 (mmHg) 128.6 ± 61.2 135.8 ± 61.6 122.7 ± 63.2 n.s.
Venous pH 7.30 ± 0.09 7.28 ± 0.11 7.32 ± 0.07 n.s.
PvO2 (mmHg) 43.2 ± 8.6 42.4 ± 10.6 43.6 ± 6.6 n.s.
Table 1. Characteristics at study enrollment and in the two groups of patients (S: survivors; NS: non 
survivors at 90 days). Data are presented as mean ± SD or frequency. n.s.= not significant. BMI, body mass 
index; COPD, Chronic obstructive pulmonary disease; MAP, mean arterial pressure; CVP, central venous 
pressure; PEEP, positive end-expiratory pressure; FiO2, inspired oxygen fraction; ScvO2, central venous O2 
saturation; PvCO2, venous partial pressure of CO2; PaCO2, arterial partial pressure of CO2; PaO2, arterial partial 
pressure of O2; PvO2, central venous partial pressure of O2.
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Profiles of specific metabolites differed significantly between NS and S (Table 3). The majority of PC and LPC 
species showed lower values at D1 and D7 in NS when compared to S at day 28, whereas increased concentrations 
of acetylcarnitine (C2) and of KYN were observed in NS on D1 and D7, respectively. Significantly lower values 
of LPC and PC were measured at D1 and D7 in NS when compared to S at day 90. There were six lipid species 
comprising saturated long-chain LPC and polyunsaturated very long-chain PC, whose levels decreased at D7 in 
both NS at 28 or 90-days.
The changes of metabolites from D1 to D7, reported in Table S3, were then compared between S and NS. 
Significant differences in metabolite levels were found (Fig. 3) (Wilcoxon test p < 0.05, FDR < 0.15). A clear neg-
ative variation was observed for KYN, whereas LPC and PC (mainly low saturated long-chain species) showed a 
positive variation in 28- and 90-day survivors (Table S4).
Association between metabolic patterns and mortality. Multivariate analysis was performed using 
Elastic Net in order to predict the outcome of the patients at 28 or 90 days. Such technique permits to weigh the 
contribution added by each metabolite to the prediction model and to set to zero the coefficients of those that are 
not predictive (Fig. 4). The coefficients can be interpreted as in a linear regression model: the higher their absolute 
value, the higher their weight in the model. Similarly, a positive coefficient denotes a positive correlation with the 
event (i.e. death at day 28 or at day 90) and vice versa. On D1, PC aa C38:1 and C4 (butyryl-acylcarnitine) had a 
strong positive correlation with 28-day mortality, whereas PC aa C40:6 and PC ae C38:0 were inversely associated 
(Fig. 4a). On D7, KYN and PC aa C42:4 were positively correlated to 28-day mortality, while PC aa C40:1 and 
PC ae C40:1 are negatively correlated (Fig. 4b). Interestingly, long chain PC, LPC molecular species and KYN 
measured on D7 were consistently associated with 90-day mortality (i.e. KYN, PC ae C44:3, PC aa C32:3, PC ae 
C40:1, LPC a C24:0) (Fig. 4c).
Integrated clinical and metabolomic determinants of mortality. We next checked for a possible 
redundancy of prognostic information among circulating metabolites and clinical variables.
Figure 5 shows the best elastic net regression models that considered both metabolites measured on D7 and 
clinical variables. For 28-day mortality (Fig. 5a), daily urinary output, plasma concentration of LPC a C24:0, and 
mean arterial pressure resulted negatively associated with the outcome, while the risk of death increased with the 
cardiovascular subcomponent of the SOFA score (need for vasoactive drugs). Interestingly, lower levels of LPC a 
Clinical variable D1 D7
Heart Rate (bpm) 103.5 ± 20.3 85.4 ± 10.3
MAP (mmHg) 75.7 ± 14.3 87.3 ± 15.8
CVP (mmHg) 11.7 ± 5.1 7.9 ± 3.7
Presence of ventilatory support (#pts) 20 13
PEEP (cmH2O) 8.8 ± 2.6 6.6 ± 4.6
FiO2 (%) 57.8 ± 15.2 44 ± 16.1
ScvO2 (%) 76.3 ± 9.3 76 ± 6.8
PvCO2 (mmHg) 47.3 ± 5.9 48.9 ± 6.2
PaCO2 (mmHg) 43.4 ± 6.7 43.3 ± 6.1
Serum lactate (mmol/L) 4 ± 2.2 1.8 ± 1.4
SOFA score 11.6 ± 2.7 6.8 ± 4
Respiratory SOFA score 2.4 ± 1 1.6 ± 0.9
Coagulation SOFA score 2.4 ± 1.1 1.6 ± 1.1
Hepatic SOFA score 1.3 ± 1.1 1.3 ± 1.4
Cardiovascular SOFA score 3.4 ± 0.9 0.6 ± 1.2
Renal SOFA score 2.1 ± 1.2 1.6 ± 1.6
Diuresis (ml/die) 2006.2 ± 1323.7 2944.7 ± 1870.2
Platelet count (× 103 cells/mm3) 63.8 ± 50.8 96.9 ± 55.9
Creatinine (mg/dL) 2.3 ± 1.1 1.8 ± 1.5
Biliuribin (mg/dL) 3 ± 3.5 4.6 ± 7.6
Arterial pH 7.4 ± 0.1 7.4 ± 0.1
PaO2 (mmHg) 115.3 ± 48.3 115 ± 44.9
Venous pH 7.4 ± 0.1 7.4 ± 0.1
PvO2 (mmHg) 45.1 ± 5.9 42.9 ± 6.3
Use of renal replacement therapy (#pts) 3 3
Table 2.  Clinical and laboratory variables at day 1 and day 7 for the 20 patients. Data are presented as 
mean ± SD. No significant differences were found between D1 and D7. MAP, mean arterial pressure; CVP, 
central venous pressure; PEEP, positive end-expiratory pressure; FiO2, inspired oxygen fraction; ScvO2, central 
venous O2 saturation; PvCO2, venous partial pressure of CO2; PaCO2, arterial partial pressure of CO2; PaO2, 
arterial partial pressure of O2; PvO2, central venous partial pressure of O2.
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C24:0 collected at D7 were the strongest predictors of 90-day mortality, whereas use of renal replacement therapy 
was positively associated with an increased risk of death (Fig. 5b). No reliable predictive models were obtained 
with metabolites and clinical parameters collected at D1.
Discussion
This study is a preliminary investigation to characterize the metabolomic profiles of patients with severe septic 
shock and multiple organ failures at the time of its development, and to integrate them with the clinical manifes-
tation characterizing this syndrome. It was meant as a preparatory study to the ongoing clinical trial (Shockomics, 
NCT02141607) aimed at elucidating early multilevel markers signatures that might help clinicians in understand-
ing the particular pathophysiology characterizing a specific clinical phenotype of septic shock, in prioritizing 
individual patient treatment, and in developing therapy that acts on specific target of the syndrome.
The present study identifies several metabolomic alterations, previously reported in patients with severe sepsis 
and septic shock7–12,15,16, supporting the feasibility and the rationale underlying our pilot study design. Profiles of 
specific metabolites measured on day 1 and 7 differed markedly between survivors and non-survivors, and some 
metabolic features appeared to be associated with mortality. Though we cannot discuss the significance of every 
single metabolite, some general comments on the main metabolic pathways and their pathological relevance to 
septic shock are warranted.
Non-survivors were characterized by a significant elevation of the polyamine pool (spermidine, putrescine), 
from D1 to D7, especially in those who died at 90 days (Table S3 and Fig. 2). Since polyamines mediate the 
complex interplay between bacterial infection and the host immune response19,20 this might suggest an altered 
regulation of pathogen-host interactions in these patients. Moreover non-survivors had increased plasma level 
of glucogenic aminoacids (Table S3 and Fig. 2), in line with relative hepatic dysfunction occurring early in sepsis 
and consequent derangement in the hepatic gluconeogenesis as response to sepsis21,22.
A peculiarity of NS at days 28 and 90 was the significant increase from D1 to D7 of plasma KYN (Table S4 
and Fig. 3). Indeed, KYN level at day 7 was almost doubled in 28-day NS compared to S. To date a clear relation 
has been made between accelerated tryptophan catabolism along the KYN pathway and inflammatory reactions. 
Bacterial products and proinflammatory cytokines upregulate indolamine 2,3-dioxygenase (IDO), the enzyme 
responsible for KYN production. IDO is critically involved in CD4+ and CD8+ effector T cell suppression as 
well as in generation and activation of regulatory T cells23,24. Recently, it has been shown that KYN plasma level 
might predict the development of sepsis in major trauma patients25, and its modulation has been associated to 
28-day mortality in critically ill patients8. Increased production of KYN has been proposed to contribute to hypo-
tension in sepsis26 and it has been associated with dysregulated immune response and impaired microvascular 
Figure 2. Heat maps of the metabolites (mean Log 2 μM) whose concentrations changed significantly from day 
1 (D1) to day 7 (D7) in survivors (S) (a) and non-survivors (NS) (b) both considering mortality at 28 days and 
90 days (Wilcoxon test p < 0.05, FDR < 0.15).
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reactivity27. We can speculate that the lower KYN concentration found in survivors may represent a favorable host 
response trait. Indeed, our study support for the first time the hypothesis that higher KYN levels are associated 
with an increased long-term mortality during septic shock. However, whether kynurenine metabolism is a path-
ogenic factor in sepsis or rather an epiphenomenon needs further evaluation.
Decreased plasma level of PC and LPC species was a prominent component of the metabolic phenotype in 
NS (Fig. 3), in accordance with an overall lipidome alterations observed in sepsis and critically ill patients7,13–16. 
Already at 24 hours after the diagnosis of septic shock and ICU admission (D1), patients who did not survive 
within 90 days showed a marked decrease in PC species, containing long chain polyunsaturated fatty acid 
(LCPUFAs), such as PC C38:6, PC C38:4, PC C36:6, that persisted at D7 with further elongation/desaturation 
products. Since LCPUFAs reduce T-cell activation and dampen inflammation28, it might be speculated that a 
decrease in PC containing LCPUFAs can hamper their protective effects, including a concerted action of either 
withdrawing pro-inflammatory eicosanoids or incrementing anti-inflammatory eicosanoids. We can reasonably 
exclude dietary-derived influence on LCPUFAs, since the difference in their concentrations were present already 
at D1, and patients were all subjected to dietary support according to standard guidelines on the treatment of 
patients with severe sepsis or septic shock18.
METABOLITE S NS pValue FDR
NS 
vs S
28 day mortality
D1
LPC a C16:1 0.657 (0.334, 0.970) 0.313 (0.291, 0.591) 0.040 0.003 ↓ 
PC aa C30:2 0.005 (0.005, 0.026) 0.099 (0.017, 0.147) 0.046 0.005 ↑ 
PC aa C38:1 0.757 (0.499, 0.936) 1.025 (0.886, 1.645) 0.028 < 10−6 ↑ 
PC aa C38:6 164.022 (131.032,174.123) 92.206 (47.999,137.945) 0.033 < 10−6 ↓ 
PC ae C38:0 2.633 (2.418, 3.202) 1.712 (1.124, 2.241) 0.015 < 10−6 ↓ 
SM C20:2 0.095 (0.068, 0.121) 0.055 (0.043, 0.088) 0.048 0.001 ↓ 
C2 5.080 (3.369, 8.774) 11.066 (8.189, 21.852) 0.048 0.028 ↑ 
D7
LPC a C16:0* 47.046 (24.384, 58.821) 18.150 (14.455, 33.212) 0.048 0.001 ↓ 
LPC a C18:0* 10.807 (6.188, 14.137) 5.684 (3.502, 7.111) 0.040 0.003 ↓ 
LPC a C24:0* 0.096 (0.086, 0.108) 0.066 (0.062, 0.085) 0.010 < 10−6 ↓ 
PC aa C32:3* 3.486 (2.769, 4.240) 2.019 (1.807, 2.486) 0.028 0.001 ↓ 
PC aa C34:4* 8.604 (6.879, 11.438) 4.150 (3.464, 5.720) 0.028 < 10−6 ↓ 
PC aa C36:4* 615.675(487.555,717.315) 369.822(340.428,463.466) 0.048 < 10−6 ↓ 
PC ae C34:3 26.979 (20.127, 31.112) 18.013 (15.057, 21.835) 0.048 0.002 ↓ 
PC ae C40:1* 1.633 (1.209, 1.706) 0.844 (0.770, 1.230) 0.010 0.012 ↓ 
PC ae C42:4 0.788 (0.679, 0.892) 0.608 (0.487, 0.663) 0.040 < 10−6 ↓ 
Kynurenine 7.680 (4.965, 8.735) 12.000 (8.745, 23.800) 0.012 < 10−6 ↑ 
90 day mortality
D1
PC aa C36:6 2.109 (1.630 , 2.435) 1.357 (0.957, 1.712) 0.033 0.0001 ↓ 
PC aa C38:4 225.147 (180.141 , 297.671) 142.022 (110.846, 217.886) 0.040 0.0106 ↓ 
PC aa C38:6 165.706 (137.786, 182.901) 107.441 (57.345, 152.421) 0.033 0.0002 ↓ 
D7
LPC a C16:0* 20.493 (6.241, 28.505) 12.308 (5.056, 16.828) 0.048 0.0002 ↓ 
LPC a C16:1 0.657 (0.314, 0.967) 0.467 (0.304, 0.610) 0.040 < 10−6 ↓ 
LPC a C18:0* 4.363 (1.679, 6.895) 2.707 (1.658, 4.038) 0.040 0.0002 ↓ 
LPC a C24:0 * 0.054 (0.051, 0.073) 0.057 (0.045, 0.066) 0.008 < 10−6 ↑ 
PC aa C32:2 22.073 (15.415, 30.845) 18.334 (12.289, 21.833) 0.033 0.0007 ↓ 
PC aa C32:3* 2.629 (1.924, 3.040) 1.826 (1.480, 2.195) 0.008 < 10−6 ↓ 
PC aa C34:3 74.941 (47.836, 87.092) 51.173 (38.172, 65.232) 0.040 0.0002 ↓ 
PC aa C34:4* 5.129 (2.8154, 5.778) 2.938 (2.173, 3.918) 0.006 0.0001 ↓ 
PC aa C36:4* 827.639 (414.531, 919.064) 461.559 (352.353, 563.834) 0.023 0.0008 ↓ 
PC aa C36:5 51.571 (28.557, 62.269) 24.106 (19.734, 33.696) 0.019 0.0004 ↓ 
PC aa C36:6 2.110 (1.630, 2.435) 1.357 (0.957, 1.712) 0.023 0.0001 ↓ 
PC ae C32:2 4.658 (3.829, 5.043) 3.726 (3.195, 4.541) 0.040 0.0003 ↓ 
PC ae C38:0 2.633 (2.293, 3.450) 2.167 (1.221, 2.341) 0.033 0.0041 ↓ 
PC ae C40:1* 0.911 (0.654, 1.276) 0.683 (0.426, 1.031) 0.008 < 10−6 ↓ 
PC ae C42:5 1.353 (1.068, 1.924) 1.138 (0.958, 1.920) 0.048 0.0006 ↓ 
PC ae C44:6 0.462 (0.296, 0.612) 0.401 (0.275, 0.552) 0.048 0.0004 ↓ 
Table 3.  Metabolite level comparison between survivors (S) and non-survivors (NS) at day 1 and at day 
7 for the 28-day and 90-day mortality. Only significant results are reported (p < 0.05, FDR < 0.15). Plasma 
concentrations are expressed in μ M and shown as median (25, 75 percentiles). The arrows indicate that the 
metabolite concentration in NS group is lower (↓ ) or higher (↑ ) with respect to S group. The symbol * marks 
significant metabolites in both mortality groups.
www.nature.com/scientificreports/
7Scientific RepoRts | 6:20391 | DOI: 10.1038/srep20391
A general explanation for these findings is that the lowered PC circulating level found in non-survivors might 
be due to reduced or unbalanced fatty acid substrates for their biosynthesis, consistent with a deregulated mito-
chondrial and/or peroxisomal beta-oxidation occurring early in sepsis29. Conversely, the decreased plasma ace-
tylcarnitine observed in 28-day survivors compared to non-survivors would indicate a general more efficient use 
of substrates for energy production and for a mitochondrial damage probably reversible in survivors30.
A further bio-signature characterizing non-survivors was their reduction over time in circulating 
mono-saturated and saturated LPCs. Such changes in LPC concentration is in concordance with Park et al.12 who 
showed a similar downward trend of LPC in 28-day non-survivors as compared to survivors in sepsis. Decreased 
Figure 3. Comparison of the absolute differences in metabolite concentrations (μM) from day 1 to day 
7 (Delta = D7–D1) in survivors (S) and non-survivors (NS) at 28 days (a) or 90 days (b). Distribution of 
differences is shown as box-plots, where the central mark is the median concentration, the edges of the box 
are the 25th and 75th percentiles, the outliers are defined as 1.5 times of interquartile range and highlighted by 
stars. Each plot represents a different metabolite. (Wilcoxon test p < 0.05, FDR < 0.15).
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LPC have been also reported in septic patients compared to healthy controls11. The well-known pro-inflammatory 
activities of LPC31–33 sound in apparent contradiction with the poor outcome (and the lower LPC levels) observed 
in sepsis. The reduction in circulating LPC may simply reflect their enhanced conversion to lysophosphatidic 
acid, which is known to induce a multitude of cellular responses through its action on immunological relevant 
cells34. It is conceivable that LPC reduction may promote an excessive immune response with detrimental effect 
in those patients who will not survive11,12.
In the multiparameter model, low unsaturated long-chain PC species and LPC a C24:0 were associated 
with long-term mortality (90 days) together with circulating KYN. Moreover, LPC a C24:0 and PC aa C32:3 
were negatively correlated to the event at 28 days and 90 days in combination with clinical variables, in par-
ticular, the cardiovascular SOFA score for the 28-day mortality model and the necessity of renal replacement 
therapy (e.g. continuous veno-venous hemofiltration, CVVH, or dialysis) during the 7 day ICU staying for the 
90-day mortality model. The recurrent decrease in LPC a C24:0 may denote an alteration in very long chain 
fatty acids, such as lignoceric acid as preferred substrates for the peroxisomal beta-oxidation. Consequently, a 
Figure 4. Elastic Net coefficients built on metabolites concentration at day 1 (a) and day 7 (b) for 28-day and 90 
days mortality (c). The MSE computed for the models are 0.21 for (a), 0.26 for (b) and 0.27 for (c).
Figure 5. Elastic Net coefficients built on metabolites concentration and clinical parameters collected at day 
7 for 28-day (a) and 90 days mortality (b). The MSE computed for the models are 0.23 for the 28-day one (a) 
and 0.24 for the 90-day (b). SOFA CARD: cardiovascular SOFA score; SOFA TOT: total SOFA score; MAP: 
mean arterial pressure; pHv: venous pH; diuresis (ml/die) collected at day 7; RRT: renal replacement therapy 
administered during the first 7 days of treatment.
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down-regulation of the peroxisomal lignoceryl-CoA ligase activity might be hypothesized. Indeed, reduced per-
oxisome proliferator-activated receptor α (PPARα ) expression has been associated with decreased survival in 
pediatric patients with septic shock35. Our findings suggest a multifactorial origin for such abnormal phospholip-
ids metabolism, in which dysregulation of phospholipases, catabolism of LPC, peroxisomal dysfunction, imbal-
ance in the levels of saturated/unsaturated fatty acids could all be involved. However, the underlying molecular 
mechanisms potentially regulating the circulating PC and LPC species in survivors as compared to non-survivors 
remain unclear and warrant further investigations.
Our study has several limitations. First, a targeted approach restricts, by its nature, the panel of candidate 
markers and focuses only on few metabolic pathways. Second, the sample size is limited, and confirmatory stud-
ies are necessary. Since many patients with such severity of septic shock do not reach day 7 of ICU staying, we 
end up with a limited number of patients fulfilling our study criteria. To note that the primary purpose of this 
investigation was to examine the feasibility of our metabolomics approach in determining changes in circulating 
metabolites able to characterize the progress of septic shock condition and to reveal the involved pathways.
Third, we measured metabolites at two time points only within one week from the diagnosis of septic shock, 
and metabolites with temporal changes out of this time window might provide a more precise insight for the clin-
ical progression of the disease. Nevertheless, we identified a combination of circulating metabolites altered during 
the early course of severe septic shock and associated with mortality.
This preliminary investigation was therefore very informative in capturing possible evolution and variations of 
metabolic signatures during a full blown, durable and well-established pathophysiologic manifestation of severe 
septic shock. Focusing on a homogeneous group of patients rather than on a larger number of scattered pheno-
types allowed for a better control of potentially confounding factors. Therefore, the metabolic changes observed 
in our samples pertains more closely to the selected pathophysiological condition and it should be proved in a 
larger cohort by including different phenotypes such as not only the severe patients and multimarkers informa-
tion such as multi-omics data.
Conclusions
In conclusion, the data presented here confirm the feasibility of our approach in determining changes circulating 
metabolites able to characterize the progress of septic shock condition. Our results are in line with recent find-
ings indicating that lipid homeostasis and tryptophan catabolism might influence mortality in septic shock. The 
association of early changes in the plasma levels of both lipid species and KYN with mortality, with possible impli-
cations for early intervention is the most important result of our study Although our analyses cannot determine 
causality, it suggests that alterations in KYN and lipid species might represent not only risk factors for patients 
with severe septic shock but important pathophysiologic mechanisms deserving further investigations.
Materials and Methods
Study design, patients and clinical data. This pilot retrospective metabolomic investigation was a sub-
study of the multicenter, randomized Albumin Italian Outcome Sepsis (ALBIOS) clinical trial, which enrolled 
patients with severe septic or septic shock from 100 ICU in Italy (NCT00707122). Details of the ALBIOS study 
and protocol are fully described in the original article4.
Inclusion criteria for the present study were the presence of septic shock36 (as defined by the presence of a 
proved or suspected infection in at least one site; two or more of the signs of systemic inflammatory reaction 
syndrome; the presence of an acute sepsis-related cardiovascular dysfunction or the presence of a systolic blood 
pressure < 90 mmHg), serum concentrations of lactate > 4 mmol/L, a total SOFA score > 8, , and with plasma 
samples available at day 1 (D1) and day 7 (D7) after diagnosis of septic shock in the ALBIOS biobank. In addition, 
we consider only patients remaining in ICU until 7 to 14 days from shock (until either ICU discharge or death). 
This allows elucidating with good accuracy and solidity the possible association of metabolite profiles with patient 
outcome, as close to blood sample collection (day 7). Exclusion criteria included the presence of active hemato-
logical malignancy or cancer, immunodepression, HIV infection, chronic renal failure, or advanced cirrhosis. 
Such inclusion and exclusion criteria were in accordance with those of the ongoing multicenter clinical study, 
ShockOmics (NCT02141607), and the current study represents a preliminary investigation.
Only 20 among the 997 patients enrolled in ALBIOS trial and with plasma samples stored in the biobank ful-
filled the inclusion criteria (see Fig. 1). The following demographic, clinical and laboratory variables were consid-
ered: (i) information about the patient collected at ICU admission: age (years), sex, body mass index, pathological 
conditions before hospitalization (presence of hepatic insufficiency, renal insufficiency, respiratory pathologies, 
immunocompromised state, cardiovascular pathologies), Simplified Acute Physiology Score (SAPS), duration of 
primary infection; (ii) hemodynamic parameters: heart rate (bpm), mean arterial pressure (mmHg), venous cen-
tral pressure (mmHg), daily urinary output (ml/die); (iii) ventilation parameters: the need for ventilatory support, 
positive end-expiratory pressure (cmH20), FiO2 (%); (iv) blood gas analysis: central venous O2 saturation, venous 
partial pressure of CO2, arterial partial pressure of CO2, arterial partial pressure of O2, central venous partial 
pressure of O2, arterial and venous pH; (v) laboratory and clinical parameters: serum concentrations of creatinine 
(mg/dL), biliuribin (mg/dL), and lactate (mmol/L), platelet count (x103 cells/mm3); (vi) Sequential Organ Failure 
Assessment Score (SOFA)37, total SOFA score and the sub-scores relating to the respiratory, coagulation, hepatic, 
cardiovascular, and renal systems; (vii) outcome: mortality at 28 and 90. Details of study population are reported 
in Table 1 and Table 2.
Outcome was defined as mortality at 28 and 90 days. For each patient, plasma samples were available at day 
1 (acute state, D1) and at day 7 (steady state; D7) after diagnosis of septic shock for the present metabolomics 
analysis.
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Target plasma metabolomics analysis. A targeted quantitative approach using a combined direct flow 
injection and liquid chromatography (LC) tandem mass spectrometry (MS/MS) assay (AbsoluteIDQ 180 kit, 
Biocrates, Innsbruck, Austria) was applied for the metabolomics analysis to EDTA-plasma samples stored at 
− 80 °C at the ALBIOS-biobank. The method combines derivatization and extraction of analytes with the selective 
mass-spectrometric detection using multiple reaction monitoring (MRM) pairs. Isotope-labeled internal stand-
ards are integrated into the platform for metabolite absolute quantification. This strategy allows simultaneous 
quantification of 186 metabolites (40 amino acids and biogenic amines, 40 acylcarnitines, 90 glycerophospho-
lipids, 15 sphingomyelins, 1 monosaccharide). A summary of the metabolomic analysis and the list of all the 
measurable metabolites are provided in Supplemental Methods.
Statistical analysis. In the present analysis, patients were analyzed according to their survival status at 28 
and 90 days after study enrollment. All quantified metabolites were considered in the analysis, together with 
the clinical parameters available at study enrollment and those related to patient condition at day 1 and at day 7 
(Tables 1 and 2).
The comparisons between survivors (S) and non-survivors (NS) were performed by unpaired Wilcoxon Test 
for clinical parameters and metabolite concentrations (μ M). The changes of the parameters from day 1 to day 7 
were evaluated by means of the paired Wilcoxon signed rank test separately for the S and NS groups. Finally, the 
variations of the metabolites concentrations were compared between S and NS group by unpaired Wilcoxon test. 
We calculated also the false discovery rate (FDR) to overcome the problem of the large number of statistical com-
parisons. To compute the FDR, we used a bootstrapping technique of oversampling with replacement to obtain a 
sample size of 20 patients for each group (S and NS).
Multivariate analysis was performed using the Elastic Net technique, a shrinkage regression method effective 
in case of several highly correlated variables38. The Elastic Net performs continuous variable selection causing 
some of the regression coefficients to be exactly zero, thus reducing the variance of the regression estimates by 
eliminating redundant predictors. Furthermore, the subset of variables corresponding to non-zero coefficients 
can be considered as the predictors mainly associated to the outcome. Firstly, metabolomics data and clinical 
parameters were normalized to have unitary variance and zero mean. Different models were built with 2, 4, 5 and 
10-fold cross validation (CV) for every data set analyzed, and the model with the minimum Mean Squared Error 
(MSE) was selected. As for the FDR, we used a bootstrapping technique of oversampling with replacement to 
obtain a sample size of 20 patients for each group (S and NS) by maintaining the same percentage of events. The 
outcome (survivors = 0, non-survivors = 1) was considered as output of the model. The best model was selected 
among the different CV models based on one-standard error rule.
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